Vertex Pharmaceuticals Incorporated logo
Vertex Pharmaceuticals Incorporated (VRTX)
Compare

Vertex Pharmaceuticals Incorporated (VRTX) EV/EBITDA Ratio: 20.92x

popular:market cap|pe ratio|revenue|price history|total return

Is Vertex Pharmaceuticals Incorporated’s EV/EBITDA ratio high or low?

Vertex Pharmaceuticals Incorporated's EV/EBITDA ratio of 20.92x is 62% below its 5-year average of 54.94x, near the low end of its 5-year range (12.66x–270.19x).

The EV/EBITDA ratio for Vertex Pharmaceuticals Incorporated (VRTX) is 20.92x as of Wednesday, June 10, 2026. It is below its 12-month average by 9.02% (22.99x).

EV/Sales|P/E Ratio|EBITDA|All Metrics

VRTX EV/EBITDA Ratio Chart

VRTX EV/EBITDA Ratio
20.92x+2.55% 1Y
Zoom

VRTX Average EV/EBITDA Ratio Chart

VRTX Current vs Average EV/EBITDA Ratio Chart

VRTX EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

20.92x

EV/EBITDA RATIO AVG TTM

22.99x

EV/EBITDA RATIO AVG 3Y

82.30x

EV/EBITDA RATIO AVG 5Y

54.94x

EV/EBITDA RATIO AVG 10Y

150.67x

EV/EBITDA RATIO AVG 15Y

142.19x

EV/EBITDA RATIO AVG 20Y

142.19x

CURRENT VS TTM AVG

-9.02%

CURRENT VS 3Y AVG

-74.58%

CURRENT VS 5Y AVG

-61.93%

CURRENT VS 10Y AVG

-86.12%

CURRENT VS 15Y AVG

-85.29%

CURRENT VS 20Y AVG

-85.29%

VRTX Competitors' EV/EBITDA Ratio

NAMEMARKET CAPEV/EBITDA RATIOTTM3Y5Y
Vertex Pharmaceuticals Incorporated (VRTX)—20.92x22.99x82.30x54.94x
Bristol-Myers Squibb Company (BMY)$114.14B10.82x9.64x16.60x15.48x
Medtronic plc (MDT)$103.04B13.03x15.68x15.65x17.02x
CVS Health Corporation (CVS)$125.16B17.45x14.88x11.86x12.00x
Danaher Corporation (DHR)$130.25B21.52x23.46x23.88x22.36x
Elevance Health Inc. (ELV)$87.43B12.44x10.05x11.31x12.23x
Cigna Corporation (CI)$78.25B8.55x8.37x9.19x9.50x
Pfizer Inc. (PFE)$146.36B12.38x10.50x15.94x13.74x
Intuitive Surgical, Inc. (ISRG)$146.44B39.06x52.49x59.81x55.90x
Gilead Sciences, Inc. (GILD)$151.21B12.54x14.17x17.98x15.97x

EV/EBITDA vs. its own history

At 20.9, EV/EBITDA is cheaper than usual — richer than 31% of its 14-year range.

14-year low

12.7

median

27.8

14-year high

2356.6

cheaperricher

Understanding EV/EBITDA

Enterprise Value (EV) = Market Cap + Total Debt - Cash

EBITDA = Earnings Before Interest, Taxes, Depreciation & Amortization

EV/EBITDA is commonly used for comparing companies because:

  • It accounts for debt levels (capital structure neutral)
  • It removes effects of different depreciation policies
  • It can be compared across countries with different tax rates
  • It can remain available when net income is negative, if EBITDA is positive

Vertex Pharmaceuticals Incorporated EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Vertex Pharmaceuticals Incorporated EV/EBITDA Ratio FAQ

What is the EV/EBITDA ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
The EV/EBITDA ratio for VRTX stock is 20.92x.
Is Vertex Pharmaceuticals Incorporated's EV/EBITDA ratio high or low?
Vertex Pharmaceuticals Incorporated's EV/EBITDA ratio of 20.92x is 62% below its 5-year average of 54.94x, near the low end of its 5-year range (12.66x–270.19x).
What is the TTM average EV/EBITDA ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
The TTM average EV/EBITDA ratio for VRTX stock is 22.99x.
What is the 3Y average EV/EBITDA ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
The 3Y average EV/EBITDA ratio for VRTX stock is 82.30x.
What is the 5Y average EV/EBITDA ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
The 5Y average EV/EBITDA ratio for VRTX stock is 54.94x.
What is the 10Y average EV/EBITDA ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
The 10Y average EV/EBITDA ratio for VRTX stock is 150.67x.
What is the 15Y average EV/EBITDA ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
The 15Y average EV/EBITDA ratio for VRTX stock is 142.19x.
What is the 20Y average EV/EBITDA ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
The 20Y average EV/EBITDA ratio for VRTX stock is 142.19x.

Vertex Pharmaceuticals Incorporated EV/EBITDA Ratio History

DATEEV/EBITDA RATIO
2026-06-1020.92x
2026-06-0921.35x
2026-06-0821.22x
2026-06-0521.41x
2026-06-0421.15x
2026-06-0320.49x
2026-06-0220.33x
2026-06-0120.99x
2026-05-2921.44x
2026-05-2821.46x
2026-05-2720.93x
2026-05-2620.87x
2026-05-2220.80x
2026-05-2120.75x
2026-05-2020.60x
2026-05-1920.79x
2026-05-1820.90x
2026-05-1520.92x
2026-05-1421.58x
2026-05-1321.71x
2026-05-1221.48x
2026-05-1120.83x
2026-05-0820.57x
2026-05-0720.33x
2026-05-0620.46x
2026-05-0520.30x
2026-05-0422.54x
2026-05-0122.23x
2026-04-3022.41x
2026-04-2922.19x
2026-04-2822.56x
2026-04-2722.34x
2026-04-2422.57x
2026-04-2322.82x
2026-04-2222.96x
2026-04-2122.90x
2026-04-2023.04x
2026-04-1723.15x
2026-04-1622.85x
2026-04-1523.17x
2026-04-1423.31x
2026-04-1323.08x
2026-04-1022.88x
2026-04-0923.44x
2026-04-0823.29x
2026-04-0722.65x
2026-04-0622.78x
2026-04-0223.01x
2026-04-0123.47x
2026-03-3123.43x
2026-03-3023.25x
2026-03-2722.71x
2026-03-2623.81x
2026-03-2523.88x
2026-03-2423.54x
2026-03-2323.68x
2026-03-2023.82x
2026-03-1924.04x
2026-03-1823.70x
2026-03-1724.27x
2026-03-1624.47x
2026-03-1324.64x
2026-03-1225.10x
2026-03-1125.86x
2026-03-1026.22x
2026-03-0924.19x
2026-03-0623.97x
2026-03-0524.19x
2026-03-0425.09x
2026-03-0324.90x
2026-03-0225.52x
2026-02-2726.09x
2026-02-2625.21x
2026-02-2525.36x
2026-02-2425.60x
2026-02-2325.26x
2026-02-2025.04x
2026-02-1924.63x
2026-02-1824.69x
2026-02-1725.06x
2026-02-1325.81x
2026-02-1225.04x
2026-02-1124.83x
2026-02-1024.95x
2026-02-0925.36x
2026-02-0625.75x
2026-02-0524.69x
2026-02-0425.34x
2026-02-0325.07x
2026-02-0225.42x
2026-01-3025.31x
2026-01-2925.62x
2026-01-2825.75x
2026-01-2725.54x
2026-01-2625.69x
2026-01-2325.22x
2026-01-2225.16x
2026-01-2124.82x
2026-01-2023.77x
2026-01-1623.73x
2026-01-1523.59x
2026-01-1424.18x
2026-01-1324.46x
2026-01-1224.79x
2026-01-0924.97x
2026-01-0825.29x
2026-01-0726.09x
2026-01-0625.22x
2026-01-0524.14x
2026-01-0224.32x
2025-12-3124.39x
2025-12-3024.41x
2025-12-2924.75x
2025-12-2624.92x
2025-12-2424.92x
2025-12-2324.71x
2025-12-2224.78x
2025-12-1924.55x
2025-12-1824.06x
2025-12-1724.18x
2025-12-1624.48x
2025-12-1524.52x
2025-12-1224.32x
2025-12-1123.98x
2025-12-1023.91x
2025-12-0923.49x
2025-12-0823.77x
2025-12-0524.51x
2025-12-0424.61x
2025-12-0324.93x
2025-12-0223.27x
2025-12-0122.86x
2025-11-2823.30x
2025-11-2623.22x
2025-11-2523.09x
2025-11-2422.77x
2025-11-2122.92x
2025-11-2022.68x
2025-11-1922.60x
2025-11-1823.41x
2025-11-1723.32x
2025-11-1423.50x
2025-11-1323.35x
2025-11-1223.33x
2025-11-1123.06x
2025-11-1022.61x
2025-11-0721.97x
2025-11-0622.34x
2025-11-0522.38x
2025-11-0422.64x
2025-11-0323.28x
2025-10-3123.26x
2025-10-3022.94x
2025-10-2922.79x
2025-10-2823.08x
2025-10-2722.95x
2025-10-2423.02x
2025-10-2323.09x
2025-10-2223.31x
2025-10-2123.30x
2025-10-2022.89x
2025-10-1722.76x
2025-10-1622.30x
2025-10-1522.26x
2025-10-1422.50x
2025-10-1322.23x
2025-10-1022.25x
2025-10-0922.65x
2025-10-0823.01x
2025-10-0722.39x
2025-10-0621.98x
2025-10-0322.00x
2025-10-0222.31x
2025-10-0122.05x
2025-09-3021.34x
2025-09-2921.55x
2025-09-2621.01x
2025-09-2520.79x
2025-09-2420.50x
2025-09-2320.67x
2025-09-2220.86x
2025-09-1920.86x
2025-09-1821.09x
2025-09-1721.09x
2025-09-1621.33x
2025-09-1521.43x
2025-09-1221.51x
2025-09-1121.67x
2025-09-1021.17x
2025-09-0921.62x
2025-09-0821.55x
2025-09-0521.60x
2025-09-0421.64x
2025-09-0321.62x
2025-09-0221.87x
2025-08-2921.31x
2025-08-2821.37x
2025-08-2721.20x
2025-08-2621.09x
2025-08-2521.19x
2025-08-2221.54x
2025-08-2121.67x
2025-08-2021.50x
2025-08-1921.29x
2025-08-1821.24x
2025-08-1521.41x
2025-08-1421.27x
2025-08-1321.58x
2025-08-1221.12x
2025-08-1120.37x
2025-08-0819.93x
2025-08-0720.44x
2025-08-0621.00x
2025-08-0520.40x
2025-05-05262.90x
2025-05-02263.41x
2025-05-01262.18x
2025-04-30267.90x
2025-04-29264.68x
2025-04-28260.91x
2025-04-25259.49x
2025-04-24258.75x
2025-04-23258.72x
2025-04-22257.68x
2025-04-21250.72x
2025-04-17256.94x
2025-04-16255.22x
2025-04-15263.06x
2025-04-14260.56x
2025-04-11254.32x
2025-04-10249.63x
2025-04-09253.29x
2025-04-08247.95x
2025-04-07249.13x
2025-04-04249.16x
2025-04-03254.21x
2025-04-02253.93x
2025-04-01254.60x
2025-03-31254.64x
2025-03-28258.87x
2025-03-27264.17x
2025-03-26262.95x
2025-03-25267.65x
2025-03-24269.10x
2025-03-21264.52x
2025-03-20268.27x
2025-03-19269.52x
2025-03-18269.37x
2025-03-17270.19x
2025-03-14265.36x
2025-03-13264.36x
2025-03-12260.34x
2025-03-11256.53x
2025-03-10262.80x
2025-03-07256.51x
2025-03-06255.12x
2025-03-05258.31x
2025-03-04255.39x
2025-03-03253.83x
2025-02-28251.94x

Showing the most recent 260 of 2,578 data points. The chart above shows the full history.

Related Metrics

EV/SalesP/E RatioEBITDAAll Metrics

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a robust and diverse clinical pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitrypsin (AAT) deficiency; VX-147, also in Phase 2, addressing APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other serious kidney conditions; VX-880, a potential treatment for Type 1 Diabetes undergoing Phase 1/2 trials; VX-548, a NaV1.8 inhibitor in Phase 2 for various forms of acute, neuropathic, and musculoskeletal pain; and CTX001, which is in Phase 3 development for severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company distributes its pharmaceutical products through specialty pharmacies and distributors across the United States, while international sales are facilitated via a network of specialty distributors, retail chains, hospitals, and clinics. Vertex also engages in numerous strategic collaborations with partners such as Affinia Therapeutics, Arbor Biotechnologies, CRISPR Therapeutics, Kymera Therapeutics, Mammoth Biosciences, Moderna, Obsidian Therapeutics, Skyhawk Therapeutics, Ribometrix, Genomics plc, Merck KGaA, and X-Chem. Established in 1989, Vertex Pharmaceuticals is headquartered in Boston, Massachusetts.

Boston, MA
6,100 employees
www.vrtx.com
Healthcare / Biotechnology
Sector
Healthcare
Industry
Biotechnology
CEO
Reshma Kewalramani
View full financials